Selank and Semax Research Review: What the Studies Show

The Selank peptide and the Semax peptide are usually mentioned in the same breath, and "Selank Semax" is a common search. They have a lot in common on paper: both are synthetic heptapeptides developed in Russia, and both end in the same Pro-Gly-Pro tail added for stability. Beyond that, they come from different parent molecules and have been studied for different questions. This review covers what each is, what the published studies report, and where that evidence stops.
Two heptapeptides, one shared design idea
Short natural peptides tend to break down quickly. The Russian groups behind both compounds took a biologically active fragment and extended it with Pro-Gly-Pro, a tripeptide intended to make the result more stable. The fragments they started from are very different, which is why the two are best read separately.
The tail is not necessarily inert. One rat study of experimental cerebral ischemia tested Pro-Gly-Pro on its own alongside Semax and reported that both were associated with transcription of neurotrophin genes (Dmitrieva et al., 2010). That makes it harder to assign any reported finding to one part of the molecule, and it is one more reason to treat mechanisms as open questions.
A practical note on reading this literature: many primary papers are in Russian, and English-language readers often see only the abstract. Abstracts rarely report blinding, randomisation or how outcomes were measured, so the honest summary of a study is often narrower than the one repeated online.
The Selank peptide: structure and proposed mechanism
Selank has the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is an analog of tuftsin, a short fragment of immunoglobulin G, extended with Pro-Gly-Pro (Volkova et al., 2016).
Its mechanism is not established. Three proposals appear in the literature:
- Enkephalin-degrading enzymes. Selank was reported to inhibit enzymes that break down enkephalins (Zozulya et al., 2001).
- GABA receptor binding. Radioligand studies suggest allosteric modulation of GABA receptor binding (Vyunova et al., 2018).
- Gene expression. Changes in the expression of genes involved in GABAergic neurotransmission were reported (Volkova et al., 2016).
Most of this mechanistic work comes from the Russian groups that developed the peptide.
Selank research in people
The human literature is small. A Russian-language study compared Selank with medazepam in 62 patients with generalised anxiety disorder or neurasthenia, 30 in the Selank group and 32 in the comparator group (Zozulia et al., 2008). The abstract does not describe blinding, so the design cannot be fully assessed from what is available in English. A 2026 review reports that Selank is approved in Russia for anxiety, citing a Russian source (Rahman et al., 2026). We found no FDA approval.
The Semax peptide: structure and proposed mechanism
Semax has the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It combines the ACTH(4-7) fragment with the Pro-Gly-Pro tail and is often described as an ACTH(4-10) analog (Dolotov et al., 2006). Despite its origin in ACTH, it lacks hormonal ACTH activity.
Most Semax research is in rats. It has been associated with increased BDNF and TrkB expression in the rat hippocampus (Dolotov et al., 2006), and with transcription of neurotrophin genes and their receptors after experimental cerebral ischemia (Dmitrieva et al., 2010). Transcriptome-level work after ischemia-reperfusion in rats extends those findings (Filippenkov et al., 2020), and a 2025 paper examined Semax and a derivative in an Alzheimer's-type animal model (Radchenko et al., 2025).
Its receptor target is not established. One cell study, discussed by Filippenkov and colleagues, found that Semax did not activate the melanocortin-4 receptor but blunted alpha-MSH signalling, which is a reminder that "ACTH analog" describes its origin, not a confirmed receptor mechanism.
Semax research in people
Semax appears on Russia's government list of vital and essential drugs (Radchenko et al., 2025). A 2026 review notes that it is not FDA-approved and that much of its clinical evidence comes from Russian studies lacking independent validation (Mavrych et al., 2026).
Selank vs Semax at a glance
| Selank | Semax | |
|---|---|---|
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Met-Glu-His-Phe-Pro-Gly-Pro |
| Parent fragment | Tuftsin (IgG fragment) | ACTH(4-7) |
| Main research areas | Anxiety-related behaviour in rodents; GABAergic gene expression; enkephalinase inhibition | Cerebral ischemia in rats; BDNF and TrkB; learning and memory in rodents |
| Mechanism | Not established; several proposals | Not established; receptor target unknown |
| Status | Reported approved in Russia; not FDA-approved | Registered in Russia; not FDA-approved |
Where the evidence stops
Read together, the two literatures share the same limits:
- Most of the work comes from the Russian groups that developed each peptide, and independent replication is limited.
- Human studies are few, small and largely in Russian-language journals, with designs that are hard to assess from English abstracts.
- Mechanisms are proposed, not established.
- There is no published research on the two peptides studied together. The Selank + Semax product contains Selank and Semax in one vial, and the literature summarised here describes each component separately, not any combined effect.
Modified forms deserve the same caution. The catalogue's NA-Semax amidate is a chemically modified Semax listed as its own product, and the Semax studies cited here should not be assumed to describe it.
Formats and specifications
Formats here describe containers and storage only. They are not instructions for use.
| Product | House code | Container | Storage |
|---|---|---|---|
| Selank | CS-SELK | Glass vial, crimp seal, flip-top cap | -20 °C, desiccated |
| Semax | CS-SEMX | Glass vial, crimp seal, flip-top cap | -20 °C, desiccated |
| Selank + Semax (5 mg / 5 mg) | CS-SLSX | Glass vial, crimp seal, flip-top cap | -20 °C, desiccated |
| Selank spray | CS-SELK-SP | 10 mL spray bottle, pump and overcap | 2 to 8 °C, protect from light |
| NA-Semax amidate spray | CS-NASX-SP | 10 mL spray bottle, pump and overcap | 2 to 8 °C, protect from light |
The vial products are lyophilised and stored frozen. The Selank spray and NA-Semax amidate spray are liquid preparations in a pump bottle and are kept refrigerated and away from light.
How each lot is characterised
Selank and Semax are both seven residues long and share their last three, so identity testing matters. Each lot's certificate confirms identity by mass spectrometry against the theoretical mass of the named sequence and states the measured purity from HPLC, with the chromatogram shown. For the blend, the chromatogram should resolve two main peaks, one for each peptide. For a full walkthrough of reading a certificate, see how to spot a fake peptide COA. Readers following other Russian-developed short peptides may also want bioregulator peptides: what the research shows.
Frequently asked questions
What is the difference between the Selank peptide and the Semax peptide?
Selank is a tuftsin analog (Thr-Lys-Pro-Arg-Pro-Gly-Pro) studied mainly for anxiety-related behaviour and GABAergic signalling. Semax is an ACTH(4-7) analog (Met-Glu-His-Phe-Pro-Gly-Pro) studied mainly in rat models of cerebral ischemia and for BDNF expression. They share only the Pro-Gly-Pro tail.
Are Selank and Semax FDA-approved?
No FDA approval was found for either. Selank is reported as approved in Russia, and Semax is on Russia's list of vital and essential drugs.
Is there research on Selank and Semax combined?
We found none. The literature describes each peptide separately, so the combined product is summarised component by component.
How strong is the human evidence?
Limited. It consists mainly of small Russian-language studies, and reviews note a lack of independent validation.
See it in the catalogue: Selank research peptide.
For laboratory research use only. Products sold by California Standard Peptides are not drugs, foods, supplements or cosmetics and are not for human or veterinary use. This article summarises published literature; it is not medical advice and not a usage guide.